Comprehensive care of ulcerative colitis: new treatment strategies.

Introduction: Ulcerative colitis is a chronic inflammatory condition of the colon driven by aberrant immune activation. Although advanced medical therapies form the cornerstone of ulcerative colitis management, unmet needs include failure to induce and sustain remission in a substantial proportion of patients and in managing acute severe ulcerative colitis. We review new treatment strategies that might improve patient outcomes in the management of moderate-to-severe ulcerative colitis.

High astrovirus diversity in an endemic bat species suggests multiple spillovers from synanthropic rodents and birds.

Beyond the role of bats as natural host reservoirs of infectious agents, the impact of viral spillover from other animal species to bats has been neglected. Given the limited virus-host specificity of astroviruses (AstVs) and their propensity for cross-species transmission, we hypothesized that AstVs could be transmitted within animal communities (rodents, birds, and bats) and that native endemic bats may be exposed to viruses hosted by other species. We investigated the presence of AstV RNA in 3,796 biological samples collected in Reunion Island from ( = 3421), an endemic free-tailed bat species, and also from small terrestrial mammals and birds: ( = 146), ( = 74), ( = 36), ( = 99), and ( = 20).

Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study.

Background: Ulcerative colitis (UC) is a chronic inflammatory condition requiring continuous treatment and monitoring. There is limited pharmacokinetic data on vedolizumab during maintenance therapy and the effect of thiopurines on vedolizumab trough concentrations is unknown.

Aim: To investigate the exposure-response relationship of vedolizumab and the impact of thiopurine withdrawal in UC patients who have achieved sustained clinical and endoscopic remission during maintenance therapy.

Infliximab and adalimumab in the treatment of fistulizing Crohn's disease: a propensity score-matched analysis from the prospective Persistence Australian National IBD Cohort (PANIC4) study.

Background/aims: There are spare data on comparative medication efficacy in fistulizing Crohn's disease (FCD), particularly with immunomodulator co-therapy. Persistence is a unique way to assess real-world outcomes.

Methods: The persistence of all dispensed biological agents were analysed from the Australian Pharmaceutical Benefits Scheme (PBS) registry data 2005-2021 for FCD.